Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/122043
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDi Fiore, Riccardo-
dc.contributor.authorDrago-Ferrante, Rosa-
dc.contributor.authorSuleiman, Sherif-
dc.contributor.authorVeronese, Nicola-
dc.contributor.authorPegreffi, Francesco-
dc.contributor.authorCalleja-Agius, Jean-
dc.date.accessioned2024-05-09T13:06:34Z-
dc.date.available2024-05-09T13:06:34Z-
dc.date.issued2024-
dc.identifier.citationDi Fiore, R., Drago-Frerrante, R., Suleiman, S., Veronese. N., Pegreffi. F., & Calleja-Agius, J. (2024). Sarcopenia in gynaecological cancers. European Journal of Surgical Oncology, 10.1016/j.ejso.2024.108403en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/122043-
dc.description.abstractGynaecological cancers (GCs) comprise a group of cancers that originate in the female reproductive organs. Each GC is unique, with different signs and symptoms, risk factors and therapeutic strategies. Worldwide, the majority of GCs are still associated with high mortality rates, especially ovarian, due to difficulty in early detection. Despite numerous studies on the underlying pathophysiology, research in the field of GCs poses unique scientific and technological challenges. These challenges require a concerted multi- and inter-disciplinary effort by the clinical, scientific and research communities to accelerate the advancement of prognostic, diagnostic, and therapeutic approaches. Sarcopenia is a multifactorial disease which leads to the systemic loss of skeletal muscle mass and function. It can be caused by malignancies, as well as due to malnutrition, physical inactivity, ageing and neuromuscular, inflammatory, and/or endocrine diseases. Anorexia and systemic inflammation can shift the metabolic balance of patients with cancer cachexia towards catabolism of skeletal muscle, and hence sarcopenia. Therefore, sarcopenia is considered as an indicator of poor general health status, as well as the possible indicator of advanced cancer. There is a growing body of evidence showing the prognostic significance of sarcopenia in various cancers, including GCs. This review will outline the clinical importance of sarcopenia in patients with GCs.en_GB
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectSarcopenia -- Pathophysiologyen_GB
dc.subjectGenerative organs, Female -- Tumors -- Diagnosisen_GB
dc.subjectGenerative organs, Female -- Cancer -- Etiologyen_GB
dc.subjectOvaries -- Canceren_GB
dc.subjectCachexiaen_GB
dc.titleSarcopenia in gynaecological cancersen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1016/j.ejso.2024.108403-
dc.publication.titleEuropean Journal of Surgical Oncologyen_GB
Appears in Collections:Scholarly Works - FacM&SAna

Files in This Item:
File Description SizeFormat 
Sarcopenia in gynaecological cancers 2024.pdf
  Restricted Access
715.59 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.